Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients ≥55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen IV busulfan (Bu) (130 mg/m(2))-IV fludarabine (Flu) (40 mg/m(2)) is associated with low morbidi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Blood Marrow Transplant
Autors principals: Alatrash, Gheath, de Lima, Marcos, Hamerschlak, Nelson, Pelosini, Matteo, Wang, Xuemei, Xiao, Lianchun, Kerbauy, Fabio, Chiattone, Alexandre, Rondon, Gabriela, Qazilbash, Muzaffar H., Giralt, Sergio A., de Padua Silva, Leandro, Hosing, Chitra, Kebriaei, Partow, Zhang, Weiqing, Nieto, Yago, Saliba, Rima M., Champlin, Richard E., Andersson, Borje S.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4261630/
https://ncbi.nlm.nih.gov/pubmed/21338705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.02.007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars